









Markets
/
Stocks
/
nasdaq-rptx
/

Repare Therapeutics Inc

RPTX

1.780USD

-0.060-3.26%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

76.47MMarket Cap

LossP/E TTM



Repare Therapeutics Inc

1.780

-0.060-3.26%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Repare Therapeutics Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Repare Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

105 / 407

Overall Ranking

224 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

3.000

Target Price

+63.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Repare Therapeutics Inc Highlights

StrengthsRisks

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.48M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 53.48M.

Overvalued

The company’s latest PE is -0.71, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 27.74M shares, decreasing 25.73% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 522.86K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.68.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 7.62, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 250.00K, representing a year-over-year decrease of 76.70%, while its net profit experienced a year-over-year decrease of 51.85%.

Score

Industry at a Glance

Previous score

7.62

Change



Financials

9.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Repare Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 8.75, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.71, which is -58.12% below the recent high of -0.30 and -26717.83% above the recent low of -191.21.

Score

Industry at a Glance

Previous score

8.75

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 105/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Repare Therapeutics Inc is 3.00, with a high of 3.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

7.00

Change

0.33

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

3.000

Target Price

+63.04%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Repare Therapeutics Inc

RPTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 4.72, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.97 and the support level at 1.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.75

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Neutral

RSI(14)

45.769

Neutral

STOCH(KDJ)(9,3,3)

33.415

Neutral

ATR(14)

0.090

Low Volatility

CCI(14)

-59.411

Neutral

Williams %R

76.000

Sell

TRIX(12,20)

0.139

Sell

StochRSI(14)

18.322

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.802

Sell

MA10

1.847

Sell

MA20

1.848

Sell

MA50

1.779

Buy

MA100

1.641

Buy

MA200

1.436

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 64.57%, representing a quarter-over-quarter decrease of 10.53%. The largest institutional shareholder is James Simons, holding a total of 522.86K shares, representing 1.22% of shares outstanding, with 48.92% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

10.33M

Blue Owl Capital Holdings LP

3.44M

+2.11%

OrbiMed Advisors, LLC

3.32M

+3.82%

Versant Ventures

2.65M

-10.82%

Redmile Group, LLC

1.59M

-15.83%

MPM Capital Inc.

1.12M

Citadel Advisors LLC

937.49K

MPM BioImpact LLC

819.92K

Acadian Asset Management LLC

681.18K

+6.38%

Renaissance Technologies LLC

Star Investors

522.86K

+75.07%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 4.38, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.